Figure 5
From: Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis
Sevoflurane modifies T cell cytokine production. Splenic T cells were prepared from C57Bl/6 mice 10 days after the booster myelin oligodendrocyte glycoprotein (MOG) immunization, and restimulated ex vivo with vehicle, with MOG35-55 peptide (20 μg/ml), or activated with antibodies to CD3 and CD28 in the presence of the indicated doses of sevoflurane. After 24 h, media levels of (A) interferon (IFN)γ and (B) interleukin (IL)-17 were determined by specific ELISA. Data are mean ± SEM of n = 4 samples per group; *P <0.05 versus 0 sevoflurane (one-way analysis of variance (ANOVA), Tukey post hoc test).